Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)

Keros Therapeutics filings provide 7 years of Net Cash Flow readings, the most recent being -$406.1 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 1488.37% to -$406.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$272.5 million, a 218.99% decrease, with the full-year FY2025 number at -$272.5 million, down 218.99% from a year prior.
  • Net Cash Flow hit -$406.1 million in Q4 2025 for Keros Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $160.6 million in Q1 2025 to a low of -$406.1 million in Q4 2025.
  • Median Net Cash Flow over the past 5 years was $900500.0 (2022), compared with a mean of $1.1 million.
  • Biggest five-year swings in Net Cash Flow: soared 5071.22% in 2023 and later plummeted 1488.37% in 2025.
  • Keros Therapeutics' Net Cash Flow stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then plummeted by 32.38% to $29.2 million in 2024, then plummeted by 1488.37% to -$406.1 million in 2025.
  • The last three reported values for Net Cash Flow were -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025) per Business Quant data.